Hydroxychloroquine, widely used to treat malaria, had been touted by President Donald Trump as a potential game changer.
Mounting evidence from clinical and observational studies suggest that it doesn’t provide any meaningful benefits for COVID-19 patients.
In a new study published May 14, researchers in France accessed the effectiveness of hydroxychloroquine in 181 adults who were hospitalized. The drug did not significantly reduce symptoms within 10 days.
A study at the Shanghai Jiao Tong University School of Medicine in China included 150 adults with mild or moderate Covid-19. Half received hydroxychloroquine and half did not. There was no difference in recovery between the two groups after 28 days. However, those that were given hydroxychloroquine experienced more adverse events.